Compare
enGene Therapeutics Inc. vs Metagenomi Therapeutics, Inc. vs Century Therapeutics, Inc. vs Agenus Inc
| Latest fiscal year | enGene Therapeutics Inc. ENGN | Metagenomi Therapeutics, Inc. MGX | Century Therapeutics, Inc. IPSC | Agenus Inc AGEN |
|---|---|---|---|---|
| Year ended | 2025-10-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $25.21M | $109.16M | $114.20M |
| Revenue growth (YoY) | n/a | -51.8% | n/m | +10.4% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -380.9% | -15.8% | -17.7% |
| Net margin | n/a | -348.5% | -8.8% | -2.7% |
| Net income | -$117.30M | -$87.87M | -$9.58M | -$3.08M |
| EPS (Diluted) | $2.29 | -$2.36 | -$0.14 | $0.00 |
| Operating cash flow | -$99.24M | -$88.89M | -$103.88M | -$77.19M |
| Free cash flow | -$100.72M | -$89.47M | -$104.72M | -$77.20M |
| Cash & equivalents | $50.15M | $41.72M | $61.85M | $3.00M |
| Total assets | $221.47M | $221.10M | $223.70M | $226.80M |
| Total liabilities | $53.76M | $62.51M | $64.77M | n/a |
| Shareholders' equity | $167.71M | $158.60M | $158.94M | -$271.11M |
| Return on year-end equity | -69.9% | -55.4% | -6.0% | n/a |
| Shares outstanding | 52.02M | 37.62M | 87.52M | 35.32M |
Revenue, most recent five fiscal years
| Fiscal year | enGene Therapeutics Inc. | Metagenomi Therapeutics, Inc. | Century Therapeutics, Inc. | Agenus Inc |
|---|---|---|---|---|
| Latest | n/a | $25.21M Ended 2025-12-31 | $109.16M Ended 2025-12-31 | $114.20M Ended 2025-12-31 |
| 1 year earlier | n/a | $52.30M Ended 2024-12-31 | $6.59M Ended 2024-12-31 | $103.46M Ended 2024-12-31 |
| 2 years earlier | n/a | $44.76M Ended 2023-12-31 | $2.23M Ended 2023-12-31 | $156.31M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $5.20M Ended 2022-12-31 | $98.02M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $295.67M Ended 2021-12-31 |